Huadong Med Acquires Rights To Bi-functional Immunotherapy in $75 Million Deal
publication date: Feb 9, 2022
Hangzhou's Huadong Medicine acquired Asia Pacific (ex-Japan) rights to a bi-functional immunotherapy from Akso Biopharma of Menlo Park, CA in a $75 million agreement. Akso's AB002, a pre-clinical stage candidate, includes a DEEP-engineered soluble PD-1 decoy receptor that traps PD-L2 and PD-L1 and an IL-15 agonist to activate natural killer cells. Huadong will be responsible for development in Asia, but the two companies will form a Joint Research Committee to oversee IND-enabling work. Huadong Medicine develops products for oncology, immunology, nephrology and diabetes indications. More details....
Stock Symbol: (SHZ: 000963)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.